Boston – September 1, 2017 – Cooley advised New Enterprise Associates (NEA) on leading Trevi Therapeutics' $50.5 million Series C financing round. The financing round included new investors Lundbeckfonden Ventures, Omega Funds, Aperture Venture Partners and TPG Biotech.
According to Trevi, the funds will be used to advance the development of Nalbuphine ER, a drug with a dual agonist/antagonist mechanism of action uniquely suited to treating itch associated in various dermatologic, metabolic, hematologic and neuropathic conditions.
“Chronic, severe pruritus is a significant unmet medical need in which there is significant strategic interest,” said Ed Mathers, a partner at NEA, in a news release. “We look forward to working with the Trevi team to further the development of Nalbuphine ER as it completes its Phase 3 development program.”
As one of the world’s largest and most active venture capital firms, NEA has developed deep domain expertise and insight into its industries of focus. It channels that knowledge into every technology and healthcare investment it makes – at any stage, in any location, around the globe.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.